阿立哌唑与洛沙平治疗首发精神分裂症对照研究

目的 探讨阿立哌唑与洛沙平治疗首发精神分裂症患者的临床疗效和安全性.方法 将120例首发精神分裂症患者随机分为两组,每组60例,研究组口服阿立哌唑治疗,对照组口服洛沙平治疗,观察6周.于治疗前及治疗第2周、4周、6周末采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降(P＜0.01),同期两组间比较差异均无显著性(P＞0.05);治疗6周末,研究组显效率70.0%、有效率90.0%,对照组分别为76.7%、91.7%,两组疗效差异无显著性(P＞0.05).两组不良反应均较轻微,研究组恶心呕吐、头晕头痛、嗜睡不良反应发生率均显著高于对照组(P＜0.05或0.01);锥体外系反应、肌强直、体质量增加、内分泌改变、月经改变和泌乳、性欲改变不良反应发生率均显著低于对照组(P＜0.01).结论 阿立哌唑治疗首发精神分裂症疗效显著且与洛沙平相当,不良反应轻微,安全性高,依从性好,可作为治疗精神分裂的一线药物在临床推广应用.

A control study of aripiprazole vs loxapine in the treatment of first-episode schizophrenia

Objective To explore the efficacy and safety of aripiprazole and oxapine in the treatment of first-episode schizophrenia. Methods 120 schizophrenics were randomly assigned to two groups of 60 patients each, research group took orally aripiprazole and control group did loxapine for 6 weeks. Effieacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2^nd , 4^th and 6^th week. Results After treatment the total and each factor scores of the PANSS of both groups lowered more significantly compared with pretreatment （P〈0.01）, there were no significant differences in contemporaneous group comparisons （P〈0.05） ; at the end of the 6^th week, obvious effective and effective rates were 70.0% and 90.0% in research and 76.7% and 91.7% in control group, which showed no significant differences （P〈0.05）. Adverse reactions of both groups were mild, the incidences of nausea, vomiting, dizzi ness, headache and hypersomnia were significantly higher in research than in control group （P〈0.05 or 0.01） ; the incidences of extrapyramidal symptoms, myotonia, weight gain, endocrine alteration, menstrual changes, lactation and sexuality changes were significantly lower in research than in control group （P〈 0.01）. Conclusion Aripiprazole has an evident effect equivalent to loxapine in the treatment of first-epi sode schizophrenia, mild adverse reactions, high safety and good compliance, and can clinically be spread and utilized as first-line drug for schizophrenia.